# Arlo Technologies, Inc.: financial statements, quarterly

ARLO · NYSE · CIK 1736946 · [Industrials](/sectors/industrials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/arlo.md) · [Financials](/companies/arlo/financials.md) · [Filings](/companies/arlo/filings.md) · [Insiders](/companies/arlo/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/arlo/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [130](/filings/0001736946-24-000046.md) | [135 d](/filings/0001736946-26-000031.md) | [124](/filings/0001736946-25-000021.md) | [127](/filings/0001736946-25-000031.md) | [138](/filings/0001736946-25-000042.md) | [122 d](/filings/0001736946-26-000031.md) | [119](/filings/0001736946-26-000050.md) | [129](/filings/0001736946-26-000060.md) | [140](/filings/0001736946-25-000042.md) | [141 d](/filings/0001736946-26-000031.md) | [150](/filings/0001736946-26-000050.md) | [156](/filings/0001736946-26-000060.md) |
| Cost of revenue | $m | [86.9](/filings/0001736946-24-000046.md) | [87.7 d](/filings/0001736946-26-000031.md) | [76.8](/filings/0001736946-25-000021.md) | [80.6](/filings/0001736946-25-000031.md) | [89.3](/filings/0001736946-25-000042.md) | [76.7 d](/filings/0001736946-26-000031.md) | [66.3](/filings/0001736946-26-000050.md) | [71.3](/filings/0001736946-26-000060.md) | [83.0](/filings/0001736946-25-000042.md) | [75.8 d](/filings/0001736946-26-000031.md) | [77.7](/filings/0001736946-26-000050.md) | [80.7](/filings/0001736946-26-000060.md) |
| Gross profit | $m | [43.1](/filings/0001736946-24-000046.md) | [47.3 d](/filings/0001736946-26-000031.md) | [47.4](/filings/0001736946-25-000021.md) | [46.9](/filings/0001736946-25-000031.md) | [48.4](/filings/0001736946-25-000042.md) | [44.9 d](/filings/0001736946-26-000031.md) | [52.7](/filings/0001736946-26-000050.md) | [58.1](/filings/0001736946-26-000060.md) | [56.5](/filings/0001736946-25-000042.md) | [65.5 d](/filings/0001736946-26-000031.md) | [72.7](/filings/0001736946-26-000050.md) | [75.2](/filings/0001736946-26-000060.md) |
| Research and development | $m | [16.8](/filings/0001736946-24-000046.md) | [16.5 d](/filings/0001736946-26-000031.md) | [20.8](/filings/0001736946-25-000021.md) | [19.6](/filings/0001736946-25-000031.md) | [17.6](/filings/0001736946-25-000042.md) | [15.3 d](/filings/0001736946-26-000031.md) | [16.2](/filings/0001736946-26-000050.md) | [18.5](/filings/0001736946-26-000060.md) | [18.1](/filings/0001736946-25-000042.md) | [20.9 d](/filings/0001736946-26-000031.md) | [22.8](/filings/0001736946-26-000050.md) | [23.7](/filings/0001736946-26-000060.md) |
| Operating income | $m | [(2.3)](/filings/0001736946-24-000046.md) | [(0.5) d](/filings/0001736946-26-000031.md) | [(10.6)](/filings/0001736946-25-000021.md) | [(12.8)](/filings/0001736946-25-000031.md) | [(5.5)](/filings/0001736946-25-000042.md) | [(6.0) d](/filings/0001736946-26-000031.md) | [(1.5)](/filings/0001736946-26-000050.md) | [1.9](/filings/0001736946-26-000060.md) | [0.9](/filings/0001736946-25-000042.md) | [4.7 d](/filings/0001736946-26-000031.md) | [7.6](/filings/0001736946-26-000050.md) | [2.5](/filings/0001736946-26-000060.md) |
| Income tax | $m | [0.0](/filings/0001736946-24-000046.md) | [0.1 d](/filings/0001736946-26-000031.md) | [0.4](/filings/0001736946-25-000021.md) | [0.2](/filings/0001736946-25-000031.md) | [0.3](/filings/0001736946-25-000042.md) | [0.1 d](/filings/0001736946-26-000031.md) | [0.5](/filings/0001736946-26-000050.md) | [(0.3)](/filings/0001736946-26-000060.md) | [0.2](/filings/0001736946-25-000042.md) | [0.3 d](/filings/0001736946-26-000031.md) | [0.4](/filings/0001736946-26-000050.md) | [0.4](/filings/0001736946-26-000060.md) |
| Net income | $m | [(1.1)](/filings/0001736946-24-000046.md) | [0.7 d](/filings/0001736946-26-000031.md) | [(9.6)](/filings/0001736946-25-000021.md) | [(11.6)](/filings/0001736946-25-000031.md) | [(4.4)](/filings/0001736946-25-000042.md) | [(4.9) d](/filings/0001736946-26-000031.md) | [(0.8)](/filings/0001736946-26-000050.md) | [3.1](/filings/0001736946-26-000060.md) | [6.9](/filings/0001736946-25-000042.md) | [5.8 d](/filings/0001736946-26-000031.md) | [14.9](/filings/0001736946-26-000050.md) | [3.0](/filings/0001736946-26-000060.md) |
| Diluted EPS | $ per share | [(0.01)](/filings/0001736946-24-000046.md) | not reported | [(0.10)](/filings/0001736946-25-000021.md) | [(0.12)](/filings/0001736946-25-000031.md) | [(0.04)](/filings/0001736946-25-000042.md) | not reported | [(0.01)](/filings/0001736946-26-000050.md) | [0.03](/filings/0001736946-26-000060.md) | [0.06](/filings/0001736946-25-000042.md) | not reported | [0.13](/filings/0001736946-26-000050.md) | [0.03](/filings/0001736946-26-000060.md) |
| Basic EPS | $ per share | [(0.01)](/filings/0001736946-24-000046.md) | not reported | [(0.10)](/filings/0001736946-25-000021.md) | [(0.12)](/filings/0001736946-25-000031.md) | [(0.04)](/filings/0001736946-25-000042.md) | not reported | [(0.01)](/filings/0001736946-26-000050.md) | [0.03](/filings/0001736946-26-000060.md) | [0.07](/filings/0001736946-25-000042.md) | not reported | [0.14](/filings/0001736946-26-000050.md) | [0.03](/filings/0001736946-26-000060.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax
- Cost of revenue: us-gaap:CostOfGoodsAndServicesSold
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-10-01) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [51.1](/filings/0001736946-24-000046.md) | [56.5](/filings/0001736946-26-000031.md) | [62.1](/filings/0001736946-25-000021.md) | [62.9](/filings/0001736946-25-000031.md) | [77.0](/filings/0001736946-25-000042.md) | [82.0](/filings/0001736946-26-000031.md) | [84.0](/filings/0001736946-25-000021.md) | [71.2](/filings/0001736946-26-000060.md) | [86.0](/filings/0001736946-25-000042.md) | [146](/filings/0001736946-26-000060.md) | [153](/filings/0001736946-26-000050.md) | [101](/filings/0001736946-26-000060.md) |
| Current assets | $m | [261](/filings/0001736946-23-000042.md) | [251](/filings/0001736946-25-000014.md) | [256](/filings/0001736946-24-000023.md) | [263](/filings/0001736946-24-000035.md) | [280](/filings/0001736946-24-000046.md) | [263](/filings/0001736946-26-000031.md) | [246](/filings/0001736946-25-000021.md) | [269](/filings/0001736946-25-000031.md) | [302](/filings/0001736946-25-000042.md) | [260](/filings/0001736946-26-000060.md) | [276](/filings/0001736946-26-000050.md) | [273](/filings/0001736946-26-000060.md) |
| Total assets | $m | [298](/filings/0001736946-23-000042.md) | [286](/filings/0001736946-25-000014.md) | [290](/filings/0001736946-24-000023.md) | [296](/filings/0001736946-24-000035.md) | [312](/filings/0001736946-24-000046.md) | [298](/filings/0001736946-26-000031.md) | [297](/filings/0001736946-25-000021.md) | [320](/filings/0001736946-25-000031.md) | [351](/filings/0001736946-25-000042.md) | [311](/filings/0001736946-26-000060.md) | [360](/filings/0001736946-26-000050.md) | [375](/filings/0001736946-26-000060.md) |
| Current liabilities | $m | [186](/filings/0001736946-23-000042.md) | [161](/filings/0001736946-25-000014.md) | [170](/filings/0001736946-24-000023.md) | [178](/filings/0001736946-24-000035.md) | [197](/filings/0001736946-24-000046.md) | [177](/filings/0001736946-26-000031.md) | [173](/filings/0001736946-25-000021.md) | [182](/filings/0001736946-25-000031.md) | [212](/filings/0001736946-25-000042.md) | [172](/filings/0001736946-26-000060.md) | [182](/filings/0001736946-26-000050.md) | [194](/filings/0001736946-26-000060.md) |
| Total liabilities | $m | [207](/filings/0001736946-23-000042.md) | [182](/filings/0001736946-25-000014.md) | [190](/filings/0001736946-24-000023.md) | [197](/filings/0001736946-24-000035.md) | [215](/filings/0001736946-24-000046.md) | [197](/filings/0001736946-26-000031.md) | [193](/filings/0001736946-25-000021.md) | [201](/filings/0001736946-25-000031.md) | [222](/filings/0001736946-25-000042.md) | [183](/filings/0001736946-26-000060.md) | [201](/filings/0001736946-26-000050.md) | [216](/filings/0001736946-26-000060.md) |
| Shareholders' equity | $m | [90.2](/filings/0001736946-24-000046.md) | [103](/filings/0001736946-26-000031.md) | [99.9](/filings/0001736946-25-000031.md) | [99.3](/filings/0001736946-25-000042.md) | [96.9](/filings/0001736946-25-000042.md) | [101](/filings/0001736946-26-000060.md) | [103](/filings/0001736946-26-000060.md) | [118](/filings/0001736946-26-000060.md) | [129](/filings/0001736946-25-000042.md) | [128](/filings/0001736946-26-000060.md) | [159](/filings/0001736946-26-000060.md) | [159](/filings/0001736946-26-000060.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-10-01) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.5 d](/filings/0001736946-24-000046.md) | [7.9 d](/filings/0001736946-26-000031.md) | [19.8](/filings/0001736946-25-000021.md) | [6.5 d](/filings/0001736946-25-000031.md) | [18.4 d](/filings/0001736946-25-000042.md) | [6.7 d](/filings/0001736946-26-000031.md) | [30.9](/filings/0001736946-26-000050.md) | [8.8 d](/filings/0001736946-26-000060.md) | [19.2 d](/filings/0001736946-25-000042.md) | [19.8 d](/filings/0001736946-26-000031.md) | [27.9](/filings/0001736946-26-000050.md) | [11.4 d](/filings/0001736946-26-000060.md) |
| Capital expenditure | $m | [0.5 d](/filings/0001736946-24-000046.md) | [0.4 d](/filings/0001736946-25-000014.md) | [0.4](/filings/0001736946-25-000021.md) | [0.3 d](/filings/0001736946-24-000035.md) | [1.0 d](/filings/0001736946-24-000046.md) | [1.1 d](/filings/0001736946-25-000014.md) | [2.8](/filings/0001736946-25-000021.md) | not reported | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | [0.0](/filings/0001736946-25-000021.md) | [0.0 d](/filings/0001736946-25-000031.md) | [0.0 d](/filings/0001736946-25-000042.md) | [4.4 d](/filings/0001736946-26-000031.md) | [15.2](/filings/0001736946-26-000050.md) | [0.9 d](/filings/0001736946-26-000060.md) | [10.7 d](/filings/0001736946-25-000042.md) | [18.8 d](/filings/0001736946-26-000031.md) | [7.3](/filings/0001736946-26-000050.md) | [22.9 d](/filings/0001736946-26-000060.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-10-02) | Q1 FY2023 (2023-04-02) | Q2 FY2023 (2023-07-02) | Q3 FY2023 (2023-10-01) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-29) | Q1 FY2025 (2025-03-30) | Q2 FY2025 (2025-06-29) | Q3 FY2025 (2025-09-28) | Q1 FY2026 (2026-03-29) | Q2 FY2026 (2026-06-28) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [88.1](/filings/0001736946-23-000042.md) | [89.7](/filings/0001736946-24-000023.md) | [92.3](/filings/0001736946-24-000035.md) | [94.2](/filings/0001736946-24-000046.md) | [96.3](/filings/0001736946-25-000021.md) | [97.8](/filings/0001736946-25-000031.md) | [99.7](/filings/0001736946-25-000042.md) | [102](/filings/0001736946-26-000050.md) | [108](/filings/0001736946-26-000060.md) | [110](/filings/0001736946-25-000042.md) | [110](/filings/0001736946-26-000050.md) | [111](/filings/0001736946-26-000060.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 107,613,304 at 2026-07-31, from the cover of the [10-Q filed 2026-08-06](/filings/0001736946-26-000060.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:47 ET. No prices; not investment advice.